

Supplemental Table 1. Demographics and baseline characteristics of men undergoing Aquablation, stratified by age.

	Men <80 years (N=1930)		Men ≥80 years (N=206)		p value
	N		N		
Age (mean, SD)	1930	67.75 (6.94)	206	83.20 (3.41)	<.0001
<u>Comorbidities</u>					
DM2 (n, %)	564	87 (15.43)	53	11 (20.75)	0.31
Cardiovascular disease (n, %)	251	35 (13.94)	26	5 (19.23)	0.56
Anxiety/Depression (n, %)	562	90 (16.01)	53	17 (32.08)	0.0032
OSA (n, %)	465	110 (23.66)	45	9 (20.00)	0.58
Autoimmune disease (n, %)	251	11 (4.38)	26	3 (11.54)	0.13
Family history of BPH (n, %)	367	114 (31.06)	30	7 (23.33)	0.38
<u>Lab values</u>					
HbA1c, %, (median, IQR)	203	5.60 (5.40-6.00)	21	5.60 (5.20-5.80)	0.52
PSA, ng/mL (median, IQR)	1395	3.70 (1.95-6.44)	112	3.50 (1.78-6.81)	0.86
PHI (median, IQR)	407	30.90 (23.67-40.92)	26	33.87 (23.65-46.11)	0.36
<u>Baseline medication use (n, %)</u>					
Alpha adrenergic antagonist	710	518 (72.96)	71	50 (70.42)	0.65
5ARI	710	132 (18.59)	71	25 (35.21)	0.0009
Daily PDE5i	619	97 (15.67)	65	5 (7.69)	0.08
Anticholinergic/beta-3 agonist	710	33 (4.65)	71	3 (4.23)	1
<u>Anticoagulation use, any (n, %)</u>					
Aspirin 81mg (n, %)	476	70 (14.71)	50	14 (28.00)	0.0146
Other antiplatelet agent eg clopidogrel, prasugrel (n, %)	476	16 (3.36)	50	3 (6.00)	0.4113
NOAC or warfarin (n, %)	476	49 (10.29)	50	13 (26.00)	0.0011
<u>Prostate and Voiding characteristics</u>					
Prostate volume (median, IQR)	1915	78.00 (56.00-110.00)	204	84.50 (63.00-109.43)	0.051
Median lobe (n, %)	1800	1137 (63.17)	191	100 (52.36)	0.0034
Degree of intravesical prostatic protrusion, of men with a median lobe (n, %)					
Small (<5mm)	588	138 (23.47)	33	9 (27.27)	0.86
Moderate (5-10)		103 (17.52)		5 (15.15)	
Large (>10mm)		347 (59.01)		19 (57.58)	
Qmax, mL/sec (median, IQR)	943	8.30 (5.30-12.40)	70	8.55 (5.80-11.30)	0.9563
PVR, mL (median, IQR)	1289	104.00 (40.00-216.00)	113	143.00 (46.00-314.00)	0.0185
Urinary retention requiring catheter or intermittent catheterization (n, %)	1722	247 (14.34)	167	39 (23.35)	0.0019

<u>Prior BPH surgery (n, %)</u>					
No	1722	1625 (94.37)	165	153 (92.73)	0.3456
Prostate artery embolization		6 (0.35)		0 (0.00)	
Photovaporization of prostate		20 (1.16)		2 (1.21)	
Simple prostatectomy		2 (0.12)		1 (0.61)	
Water vapor thermotherapy (“Rezum”)		21 (1.22)		2 (1.21)	
Transurethral incision of prostate		1 (0.06)		0 (0.00)	
Transurethral microwave therapy		2 (0.12)		0 (0.00)	
Transurethral resection of prostate		17 (0.99)		5 (3.03)	
Prostatic urethral lift (“Urolift”)		27 (1.57)		2 (1.21)	
Robotic waterjet therapy (“Aquablation”)		1 (0.06)		0 (0.00)	
<u>Baseline patient reported outcome measures</u>					
IPSS (mean, SD)	1515	20.45 (7.63)	137	19.64 (7.87)	0.2327
IPSS QoL (median, IQR)	531	4.00 (3.00- 5.00)	53	4.00 (3.00- 5.00)	0.5515
SHIM (mean, SD)	873	14.73 (8.01)	56	7.71 (7.84)	<.0001

DM2 = diabetes mellitus, type 2. OSA = obstructive sleep apnea. HbA1c = hemoglobin A1c. PSA = prostate specific antigen. PHI = prostate health index. 5ARI = 5 alpha reductase inhibitor. PDE5i = phosphodiesterase type 5 inhibitor. NOAC = novel oral anticoagulant. Qmax = maximum urinary flow rate.